{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T14:09:13Z","timestamp":1772892553305,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T00:00:00Z","timestamp":1600819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T00:00:00Z","timestamp":1600819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s11096-020-01157-3","type":"journal-article","created":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T02:02:32Z","timestamp":1600826552000},"page":"263-269","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Evaluation of a trough-only extrapolated area under the curve vancomycin dosing method on clinical outcomes"],"prefix":"10.1007","volume":"43","author":[{"given":"Jacob","family":"Lines","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Burchette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan M.","family":"Kullab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2626-7390","authenticated-orcid":false,"given":"Paul","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,23]]},"reference":[{"key":"1157_CR1","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1310\/hpj4409-751","volume":"44","author":"CA DeRyke","year":"2009","unstructured":"DeRyke CA, Alexander DP. Optimizing vancomycin dosing through pharmacodynamic assessment targeting area under the concentration-time curve\/minimum inhibitory concentration. Hosp Pharm. 2009;44:751\u201365.","journal-title":"Hosp Pharm"},{"key":"1157_CR2","doi-asserted-by":"publisher","first-page":"182e1","DOI":"10.1016\/j.amjmed.2009.05.031","volume":"123","author":"KA Hazlewood","year":"2010","unstructured":"Hazlewood KA, Brouse SD, Pitcher WD, Hall RG. Vancomycin-associated nephrotoxicity: grave concern or death by character assassination? Am J Med. 2010;123:182e1\u20137.","journal-title":"Am J Med"},{"key":"1157_CR3","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/cid\/ciu398","volume":"59","author":"TP Lodise","year":"2014","unstructured":"Lodise TP, Drusano GL, Zasowski E, Dihmess A, Lazariu V, Cosler L, et al. Vancomycin exposure in patients with methicillin-resistance Staphylococcus aureus bloodstream infections: how much is enough? Clin Infect Dis. 2014;59:666\u201375.","journal-title":"Clin Infect Dis"},{"key":"1157_CR4","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2165\/00003088-200443130-00005","volume":"43","author":"PA Moise-Broder","year":"2004","unstructured":"Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcoc aureus lower respiratory tract infections. Clin Pharmacokinet. 2004;43:925\u201342.","journal-title":"Clin Pharmacokinet"},{"key":"1157_CR5","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2146\/ajhp080434","volume":"66","author":"M Rybak","year":"2009","unstructured":"Rybak M, Lomaestro B, Rotschafer JC, Moellering R, Craig W, Billeter M, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66:82\u201398.","journal-title":"Am J Health Syst Pharm"},{"key":"1157_CR6","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1093\/cid\/cir034","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52:285\u201392.","journal-title":"Clin Infect Dis"},{"key":"1157_CR7","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","volume":"77","author":"MJ Rybak","year":"2020","unstructured":"Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2020;77:835\u201364.","journal-title":"Am J Health Syst Pharm"},{"key":"1157_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3410\/M4-4","volume":"4","author":"A Dhand","year":"2012","unstructured":"Dhand A, Sakoulas G. Reduced vancomycin susceptibility among clinical Staphylococcus aureus isolates (\u2018the MIC Creep\u2019): implications for therapy. F1000 Med Rep. 2012;4:4.","journal-title":"F1000 Med Rep"},{"key":"1157_CR9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/FTD.0000000000000359","volume":"39","author":"A Bel Kamel","year":"2017","unstructured":"Bel Kamel A, Bourguignon L, Marcos M, Ducher M, Goutelle S. Is trough concentration of vancomycin predictive of the area under the curve? A clinical study in elderly patients. Ther Drug Monit. 2017;39:83\u20137.","journal-title":"Ther Drug Monit"},{"key":"1157_CR10","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1093\/ajhp\/zxz184","volume":"76","author":"BR Dalton","year":"2019","unstructured":"Dalton BR, Dersch-Mills D, Langevin A, Sabuta D, Rennert-May E, Greiner T. Appropriateness of basing vancomycin dosing on area under the concentration\u2013time curve. Am J Health Syst Pharm. 2019;76:1718\u201321.","journal-title":"Am J Health Syst Pharm"},{"key":"1157_CR11","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1128\/AAC.01602-07","volume":"52","author":"TP Lodise","year":"2008","unstructured":"Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother. 2008;52:1330\u20136.","journal-title":"Antimicrob Agents Chemother"},{"key":"1157_CR12","doi-asserted-by":"publisher","first-page":"5475","DOI":"10.1128\/AAC.00168-11","volume":"55","author":"JA Bosso","year":"2011","unstructured":"Bosso JA, Nappi J, Rudisill C, Wellein M, Bookstaver PB, Swindler J, et al. Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial. Antimicrob Agents Chemother. 2011;55:5475\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"1157_CR13","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1128\/AAC.01568-12","volume":"57","author":"SJ Van Hal","year":"2013","unstructured":"Van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother. 2013;57:734\u201344.","journal-title":"Antimicrob Agents Chemother"},{"key":"1157_CR14","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1179\/1973947814Y.0000000182","volume":"27","author":"L Meng","year":"2015","unstructured":"Meng L, Fang Y, Chen Y, Zhu H, Long R. High versus low vancomycin serum trough regimen for Gram-positive infections: a meta-analysis. J Chemother. 2015;27:213\u201320.","journal-title":"J Chemother"},{"key":"1157_CR15","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/phar.1638","volume":"35","author":"JP Prybylski","year":"2015","unstructured":"Prybylski JP. Vancomycin trough concentration as a predictor of clinical outcomes in patients with Staphylococcus aureus bacteremia: a meta-analysis of observational studies. Pharmacotherapy. 2015;35:889\u201398.","journal-title":"Pharmacotherapy"},{"key":"1157_CR16","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.cmi.2015.04.003","volume":"21","author":"T Steinmetz","year":"2015","unstructured":"Steinmetz T, Eliakim-raz N, Goldberg E, Leibovici L, Yahav D. Association of vancomycin serum concentrations with efficacy in patients with MRSA infections: a systematic review and meta-analysis. Clin Microbiol Infect. 2015;21:665\u201373.","journal-title":"Clin Microbiol Infect"},{"key":"1157_CR17","doi-asserted-by":"publisher","first-page":"e0146224","DOI":"10.1371\/journal.pone.0146224","volume":"11","author":"P Men","year":"2016","unstructured":"Men P, Li HB, Zhai SD, Zhao RS. Association between the AUC0-24\/MIC ratio of vancomycin and its clinical effectiveness: a systematic review and meta-analysis. PLoS ONE. 2016;11:e0146224.","journal-title":"PLoS ONE"},{"key":"1157_CR18","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1097\/FTD.0000000000000500","volume":"40","author":"P Lewis","year":"2018","unstructured":"Lewis P. Vancomycin area under the curve simplified. Ther Drug Monit. 2018;40:377\u201380.","journal-title":"Ther Drug Monit"},{"key":"1157_CR19","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1093\/jac\/dks495","volume":"68","author":"GR Matzke","year":"2013","unstructured":"Matzke GR, McGory RW, Halstenson CE, Keane WF. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother. 2013;68:743\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"1157_CR20","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1128\/AAC.21.4.575","volume":"21","author":"RA Blouin","year":"1982","unstructured":"Blouin RA, Bauer LA, Miller DD, Record KE, Griffen WO Jr. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother. 1982;21:575\u201380.","journal-title":"Antimicrob Agents Chemother"},{"key":"1157_CR21","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1128\/AAC.23.4.603","volume":"23","author":"N Brown","year":"1983","unstructured":"Brown N, Ho DH, Fong KL, Bogerd L, Maksymiuk A, Bolivar R, et al. Effects of hepatic function on vancomycin clinical pharmacology. Antimicrob Agents Chemother. 1983;23:603\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"1157_CR22","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1128\/AAC.22.3.391","volume":"22","author":"JC Rotschafer","year":"1982","unstructured":"Rotschafer JC, Crossley K, Zaske DE, Mead K, Sawchuk RJ, Solem LD. Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations. Antimicrob Agents Chemother. 1982;22:391\u20134.","journal-title":"Antimicrob Agents Chemother"},{"key":"1157_CR23","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/j.1552-4604.1980.tb01696.x","volume":"20","author":"DJ Krogstad","year":"1980","unstructured":"Krogstad DJ, Moellering RC Jr, Greenblatt DJ. Single-dose kinetics of intravenous vancomycin. J Clin Pharmacol. 1980;20:197\u2013201.","journal-title":"J Clin Pharmacol"},{"key":"1157_CR24","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/00007691-199410000-00013","volume":"16","author":"MP Ducharme","year":"1994","unstructured":"Ducharme MP, Slaughter RL, Edwards DJ. Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight. Ther Drug Monit. 1994;16:513\u20138.","journal-title":"Ther Drug Monit"},{"key":"1157_CR25","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.2146\/ajhp040555","volume":"62","author":"CA Bond","year":"2005","unstructured":"Bond CA, Raehl CL. Clinical and economic outcomes of pharmacist-managed aminoglycoside or vancomycin therapy. Am J Health Syst Pharm. 2005;62:1596\u2013605.","journal-title":"Am J Health Syst Pharm"},{"key":"1157_CR26","doi-asserted-by":"publisher","first-page":"e0203453","DOI":"10.1371\/journal.pone.0203453","volume":"13","author":"A Komoto","year":"2018","unstructured":"Komoto A, Maiguma T, Teshima D, Sugiyama T, Haruki Y. Effects of pharmacist intervention in Vancomycin treatment for patients with bacteremia due to Methicillin-resistant Staphylococcus aureus. PLoS ONE. 2018;13:e0203453.","journal-title":"PLoS ONE"},{"key":"1157_CR27","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1097\/FTD.0000000000000750","volume":"42","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Wang T, Zhang D, You H, Dong Y, Liu Y, et al. Therapeutic drug monitoring coupled with bayesian forecasting could prevent vancomycin-associated nephrotoxicity in renal insufficiency patients: a prospective study and pharmacoeconomic analysis. Ther Drug Monit. 2020;42:600\u20139.","journal-title":"Ther Drug Monit"},{"key":"1157_CR28","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1093\/ajhp\/52.13.1433","volume":"52","author":"JJ Maswoswe","year":"1995","unstructured":"Maswoswe JJ, Okpara AU. Enforcing a policy for restricting antimicrobial drug use. Am J Health Syst Pharm. 1995;52:1433\u20135.","journal-title":"Am J Health Syst Pharm"},{"key":"1157_CR29","first-page":"355","volume":"41","author":"CH Liao","year":"2008","unstructured":"Liao CH, Huang YT, Chu FY, Lin TH, Hsueh PR. Lack of increase in time to blood culture positivity in a patient with persistent methicillin-resistant Staphylococcus aureus bacteremia predicts failure of antimicrobial therapy. J Microbiol Immunol Infect. 2008;41:355\u20137.","journal-title":"J Microbiol Immunol Infect"},{"key":"1157_CR30","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1111\/1469-0691.12608","volume":"20","author":"MS Hsu","year":"2014","unstructured":"Hsu MS, Huang YT, Hsu HS, Liao CH. Sequential time to positivity of blood cultures can be a predictor of prognosis of patients with persistent Staphylococcus aureus bacteraemia. Clin Microbiol Infect. 2014;20:892\u20138.","journal-title":"Clin Microbiol Infect"},{"key":"1157_CR31","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1007\/s10096-012-1648-0","volume":"31","author":"SH Choi","year":"2012","unstructured":"Choi SH, Chung JW. Time to positivity of follow-up blood cultures in patients with persistent Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis. 2012;31:2963\u20137.","journal-title":"Eur J Clin Microbiol Infect Dis"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-020-01157-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-020-01157-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-020-01157-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T00:46:46Z","timestamp":1632358006000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-020-01157-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,23]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["1157"],"URL":"https:\/\/doi.org\/10.1007\/s11096-020-01157-3","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,23]]},"assertion":[{"value":"10 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}